Prestige Brands Holdings, Inc. — Form 10-Q Summary
Filing identity: The supplied filing is for Prestige Brands Holdings, Inc. (now identified in the request metadata as Prestige Consumer Healthcare Inc.). The reporting period is the third quarter of fiscal 2014, ended December 31, 2013, with comparative results for the three and nine months ended December 31, 2012. Amounts below are in U.S. dollars.
Business context and financial performance
The company markets and distributes over-the-counter healthcare and household cleaning products. It reports OTC Healthcare and Household Cleaning segments. It acquired Australia-based Care Pharmaceuticals on July 1, 2013; the acquisition’s pro forma effect on revenue and earnings was not material.
| Metric | Three months ended Dec. 31, 2013 | Three months ended Dec. 31, 2012 | Nine months ended Dec. 31, 2013 | Nine months ended Dec. 31, 2012 |
|---|---|---|---|---|
| Total revenue | $146.2 million | $160.2 million | $457.6 million | $469.1 million |
| Gross profit / margin | $81.8 million / 56.0% | $85.0 million / 53.0% | $260.0 million / 56.8% | $259.1 million / 55.2% |
| Operating income | $40.5 million | $46.7 million | $143.7 million | $141.7 million |
| Net income | $3.1 million | $12.3 million | $56.6 million | $46.2 million |
| Diluted EPS | $0.06 | $0.24 | $1.08 | $0.90 |
| Cash from operations | Not presented for quarter | Not presented for quarter | $80.9 million | $100.9 million |
Quarterly revenue fell 8.7%; OTC Healthcare revenue declined 9.7% and Household Cleaning revenue declined 2.8%. Management cited a weak cough-and-cold season, competition from products returning after recalls, declines in several brands, and an estimated $10 million impact from lower retailer inventory. For the nine-month period, revenue declined 2.4%, while operating income increased 1.4% and net income increased 22.7%.
Gross margin improved in both comparison periods, primarily from sourcing savings and product mix, including Care Pharma products. However, lower sales volumes and increased advertising and promotion pressured contribution margin: down 8.5% in the quarter and 1.3% year to date. Nine-month net income benefited from lower interest expense and a one-time $8.9 million tax benefit related to a state tax law change.
Liquidity, cash flow and debt
At December 31, 2013, cash and cash equivalents were $94.4 million, current assets were $244.5 million and current liabilities were $134.1 million. Principal debt was $1.033 billion, compared with $978.0 million at March 31, 2013; the company reported $57.5 million of remaining borrowing capacity under its $95 million ABL revolver. Long-term debt, net of unamortized discount, was $981.5 million, with $48.3 million classified as current.
Nine-month operating cash flow was $80.9 million, down $20.0 million year over year, mainly due to working-capital increases and lower non-cash charges. Investing used $57.9 million, including $55.2 million for the Care Pharma acquisition. Financing provided $55.5 million, including $400 million of new 5.375% senior notes due 2021, offset by debt repayments and refinancing costs.
The company redeemed $201.7 million of its 8.25% 2010 Senior Notes in December 2013 and redeemed the remaining $48.3 million on January 16, 2014. The quarter included a $15.0 million loss on early debt extinguishment; management expected an additional approximately $3.3 million loss in the following quarter. The refinancing lowered borrowing costs, but increased total reported principal debt. The company stated it was in compliance with debt covenants at December 31, 2013.
Outlook, commentary and risks
- Management estimated a 36.2% effective tax rate for the remaining quarter of fiscal 2014. The filing provides no specific revenue or earnings guidance.
- A supplier that packages products representing approximately 8% of sales stopped production in mid-January 2014. The company was qualifying alternative sources and allocating safety stock; it did not expect a material effect in fiscal Q4, but warned of possible material effects in future periods if the disruption continued.
- Key risks include competition and private-label products, retailer inventory decisions, dependence on major customers (Walmart represented 19.7% of nine-month gross sales), third-party manufacturing and supply continuity, high indebtedness, interest-rate exposure, and potential impairment of goodwill and intangibles. A one-percentage-point increase in rates on variable-rate debt was estimated to reduce pre-tax earnings and cash flow by approximately $0.8 million for the quarter and $6.6 million for the nine-month period.
- Goodwill and intangible assets totaled approximately $1.586 billion, substantially all of which management said was subject to impairment testing. No impairment charge was recorded for the nine months ended December 31, 2013.
- Management disclosed revisions to certain prior-period condensed consolidating information involving intercompany transactions, but concluded they were not material to the consolidated financial statements; consolidated financial statements were unchanged.
Investor facts to verify
- Whether the post-quarter supplier disruption was resolved, and whether alternative manufacturing capacity maintained product availability.
- Whether retailer inventory reductions and the competitive return of recalled products continued to weigh on sales after December 31, 2013.
- The final debt-extinguishment charge, post-refinancing debt balance, interest costs and covenant headroom following the January 2014 note redemption.
- Whether Care Pharma delivered the expected contribution and integration benefits, and whether its preliminary purchase-price allocations changed.
- Whether the one-time state tax benefit, acquisition-related costs and other unusual items distort comparisons of recurring earnings and cash generation.
- The filing’s reported nine-month contribution-margin percentage appears inconsistent with the stated dollar amounts; verify the underlying calculation before relying on that percentage.